(1825 - 1919)
Meteorólogo. Precursor en Cuba de las investigaciones en ese campo, dedicó gran parte de su actividad científica a la Zoología, la Geografía y la Etnología. Como geógrafo elaboró en 1848 un Atlas con 28 mapas litografiados para las escuelas primarias que fue el primero de su tipo impreso en Cuba
Biomedical Sciences
1989 | Invention and production of group B anti-meningococcal vaccine
Main executives entity: "Carlos J. Finlay" Institute
Main author: Concepción Campa Huergo
Summary: After many years of hard and careful research work, a group of Cuban researchers was able to conceive a vaccine, which is the first one obtained in the world against the meningococcus of group B. Until the Cuban discovery of group B antimeningococcal vaccine, the vaccine against this disease was limited to other groups in the world, with vaccines developed by United States and France. Among the antibacterial vaccines, the Cuban vaccine is registered as one of the most effective worldwide (80-98%). This has been checked by many field studies, according to the norms of the World Health Organization. It also presents a wide protective spectrum against the different serotypes of group B. Nowadays, it is conjugated to the polysaccharide that also protects against that one caused by meningococcus type C, and it is commercialized as VAMENGOC-BC, (the Center of Genetic Engineering and Biotechnology collaborated in the increase of the production of polysaccharide C. The production level reached allowed that all high-risk Cuban population was vaccined before the end of 1990, and that it was established since 1989 the exportation toward demanding countries. In recognition to this vaccine's quality and for the social value that its invention represents for human health, it was granted to their inventors the Gold Medal of the World Organization of Intelectual Property PERFORMERS: National Center of Antimeningococcal Vaccine
Regresar